Clinical Trial Update: Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating combination chemotherapy with or without PSC 833 in relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• PSC 833 (valspodar)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 3 | Status: COMPLETED